Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility

Several top execs from Germany's Boehringer Ingelheim turned out at the company's U.S. headquarters in Connecticut to rub shoulders with the governor and other local officials as they touted plans for a $42.5 million research facility. Described as a safety assessment center, Boehringer is adding 63,000 square feet of space to support its R&D work in the area--a welcome development for a state that had been rattled by Pfizer's plans to slash its work in Groton.

"The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut," said Governor Dannel P. Malloy, in a story by the Ridgefield Press. "This new facility expands the company's research and development capacities, and reaffirms its reputation as an innovative and forward-looking company. Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state's bioscience industry."

Boehringer, not to be left behind in making bold pronouncements, boasted that the facility will combine "state-of-the-art technology, compliance with current good manufacturing practice and process flexibility to handle production of the many different types of APIs discovered in research," according to news reports.

- here's the story from the Ridgefield Press

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.